Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen

This article was originally published in PharmAsia News

Executive Summary

FDA has deemed FibroGen's response to a clinical hold on two oral anemia therapy candidates complete, allowing Phase II trials of the compounds to resume, FibroGen's development partner, Astellas Pharma, announced April 2

You may also be interested in...

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.

Astellas Taps Pfizer Exec To Run New Global Development HQ

Long-time Pfizer exec Steven Ryder will become president of Astellas Pharma's new headquarters for global development in Deerfield, Ill., effective April 1, the Tokyo-based company announced March 4

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts